Jump Trading’s Achillion Pharmaceuticals ACHN Stock Holding History

Jump Trading’s Portfolio ACHN Stock Details ACHN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-4,700	Closed	-$42K	–	1126
2015 Q2	$42K	Buy	+4,700	New	+$44.5K	﹤0.01%	980
2015 Q1	–	Sell	-1,200	Closed	-$14K	–	997
2014 Q4	$14K	Sell	1,200 -25,500	-96%	-$311K	﹤0.01%	905
2014 Q3	$266K	Buy	26,700 +13,200	+98%	+$123K	0.01%	559
2014 Q2	$102K	Buy	+13,500	New	+$53.9K	﹤0.01%	638

Other funds holding ACHN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Jump Trading's ACHN Position: Q4 2018 in Review

Jump Trading sold out of Achillion Pharmaceuticals (ACHN) in Q4 2018, closing a stake of 10,300 shares — an estimated $38K sold.

Jump Trading first reported a position in ACHN in Q2 2014 and held it in 4 quarters. The position peaked at $167K in Q3 2014. 121 funds tracked by Wall St. Rank hold ACHN as of Q4 2018.

Jump Trading reported no remaining Achillion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Jump Trading sold 10,300 Achillion Pharmaceuticals shares in Q4 2018, an estimated $38K.
Jump Trading first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 4 quarters.
Jump Trading's Achillion Pharmaceuticals position peaked at $167K in Q3 2014.
121 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2018.

Based on Jump Trading's 13F filing for Q4 2018, filed 14 Feb 2019.